Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00487058 | A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 28 | — | — | May 1, 2007 | - | Nov 19, 2009 | 1 | Japan |
| NCT00441610 | An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor | PHASE1 | COMPLETED | 4 | — | — | Jan 1, 2007 | - | Dec 19, 2020 | 1 | Japan |
| NCT00410358 | A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor. | PHASE1 | COMPLETED | 19 | — | — | Jun 1, 2006 | - | Dec 19, 2020 | 1 | Japan |
| Arm | Type | Description |
|---|---|---|
| Gimatecan | EXPERIMENTAL | - |
| LBQ707 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Gimatecan | DRUG | - |
Inclusion criteria * Patients with histological or cytological confirmed advanced solid tumors, which progressed despite standard therapy or for whom no standard therapy exists * Life expectancy of at least 3 months * No dysfunction of bone marrow * No major impairment of renal and hepatic function...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |